

Oct 21, 2016

Buy Around:	152
SL:	138
Target:	181
Upside:	19%
Horizon:	1 Month

## VALUE PARAMETERS

Price (Rs)	147.85
52 W H/L(Rs)	201.30/79.00
Mkt. Cap.(Rs Cr)	1524.33
Latest Equity(Subscribed)	10.31
Latest Reserve (cons.)	402.31
Latest EPS (cons.) -Unit Curr.	7.93
Latest P/E Ratio -cons	18.65
Latest Bookvalue (cons.) -Unit Curr.	40.02
Latest P/BV - cons	3.69
Dividend Yield -%	0.34
Face Value	1

## STOCK DATA

BSE Code	506197
NSE Symbol	BLISSGVS
Reuters	BLIS.BO
Bloomberg	BLIS IN

## SHARE HOLDING PATTERN (%)

Description as on	% of Holding
	30/09/2016
Foreign	7.23
Institutions	0.13
Govt Holding	0.00
Non Promoter Corp. Hold.	12.32
Promoters	60.16
Public & Others	20.16

The management of the company is very positive towards the growth due to successfully sustainable business relationships across the globe which would provide the backbone for continues future growth to the company. Moreover, According to the Government of India's 'Pharma Vision 2020' aim to make India a destination for end to end solutions in pharmaceutical manufacturing and government's 'Make in India' initiative would give more complements to encouraging pharmaceutical manufacturing.

## Business Profile

BLISS GVS PHARMA Limited is a fast-growing pharmaceutical company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market.

## INVESTMENT RATIONALE

- The company's investment in primary healthcare services in Eastern Africa through its subsidiary Bliss GVS Clinic Healthcare presents a lucrative opportunity to leverage on the established brand name in a segment which is in short supply. An opportunity to replicate this model in other markets presents additional growth prospects for this business.
- It has achieved 30% CAGR over the last seven years and management strongly believe that growing customer demands, enhanced R&D and production capabilities and expanded product portfolio across dosage forms and therapeutic segments would give further strength to the company.
- Its portfolio comprises 250+ products that are consumed across 64 countries. Specifically, for the Suppositories and Pessaries dosage form and its brands are recognized among the leading ones in the generic anti-malarial segment in most African countries.
- Its 85% revenues come from Africa, Russia & South Asian markets. It also manufacturers wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products, which had remarkable presence in south asian market.

## TECHNICAL TRENDS



We recommend a buy in the stock of BLISS GVS PHARMA for a short-term perspective. The stock is trading at its good support level with good fundamental records and is expected to move up from this level. It made a 52 week low Rs. 79.00 and 52 week high of Rs 201.30. Buy around at 152 with a closing below stop loss of Rs.138 levels for the target of Rs.181.

### Note:

- Follow Strict Stop Loss.

## SMC Research Desk

E-mail: [researchfeedback@smcindiaonline.com](mailto:researchfeedback@smcindiaonline.com)



**Corporate Office:**  
11/6B, Shanti Chamber,  
Pusa Road, New Delhi - 110005  
Tel: +91-11-30111000  
[www.smcindiaonline.com](http://www.smcindiaonline.com)

**Mumbai Office:**  
Dheeraj Sagar, 1st Floor,  
Opp. Goregaon sports club, link road  
Malad (West), Mumbai - 400064  
Tel: 91-22-67341600, Fax: 91-22-28805606

**Kolkata Office:**  
18, Rabindra Sarani,  
"Poddar Court", Gate No. 4,  
4th Floor, Kolkata - 700001  
Tel: 91-33-39847000, Fax: 91-33-39847004

SMC Global Securities Ltd. (hereinafter referred to as "SMC") is a registered Member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited and its associate is member of MCX stock Exchange Limited. It is also registered as a Depository Participant with CDSL and NSDL. Its associates merchant banker and Portfolio Manager are registered with SEBI and NBFC registered with RBI. It also has registration with AMFI as a Mutual Fund Distributor.

SMC Global Securities Limited is a registered entity with SEBI for Research Analyst in terms of SEBI (Research Analyst) Regulations, 2014 vide registration number INH100001849. SMC Global Securities Limited or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing/dealing in securities Market. SMC or its associates including its relatives/analyst do not hold any financial interest/beneficial ownership of more than 1% in the company covered by Analyst. SMC or its associates and relatives does not have any material conflict of interest. SMC or its associates/analyst has not received any compensation from the company covered by Analyst during the past twelve months. The subject company has not been a client of SMC during the past twelve months. SMC or its associates has not received any compensation or other benefits from the company covered by analyst or third party in connection with the research report. The Analyst has not served as an officer, director or employee of company covered by Analyst and SMC has not been engaged in market making activity of the company covered by Analyst. The views expressed are based solely on information available publicly available/internal data/ other reliable sources believed to be true. SMC does not represent/ provide any warranty express or implied to the accuracy, contents or views expressed herein and investors are advised to independently evaluate the market conditions/risks involved before making any investment decision.

**Disclaimer:** This report is for the personal information of the authorized recipient and doesn't construe to be any investment, legal or taxation advice to you. It is only for private circulation and use. The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. No action is solicited on the basis of the contents of the report. The report should not be reproduced or redistributed to any other person(s) in any form without prior written permission of the SMC. The contents of this material are general and are neither comprehensive nor inclusive. Neither SMC nor any of its affiliates, associates, representatives, directors or employees shall be responsible for any loss or damage that may arise to any person due to any action taken on the basis of this report. It does not constitute personal recommendations or take into account the particular investment objectives, financial situations or needs of an individual client or a corporate/s or any entity/s. All investments involve risk and past performance doesn't guarantee future results. The value of, and income from investments may vary because of the changes in the macro and micro factors given at a certain period of time. The person should use his/her own judgment while taking investment decisions. Please note that we and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material; (a) from time to time, may have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned here in or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company (ies) discussed herein or may perform or seek to perform investment banking services for such company(ies) or act as advisor or lender/borrower to such company(ies) or (c) may have any other potential conflict of interest with respect to any recommendation and related information and opinions. All disputes shall be subject to the exclusive jurisdiction of Delhi High court.